Evidence map›Paper›PMID 32544303›Full record

ArticleJournal of the International AIDS Society2020

Preferences for long-acting Pre-Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment.

Alexandra M Minnis, Millicent Atujuna, Erica N Browne, Sheily Ndwayana, Miriam Hartmann, Siyaxolisa Sindelo, Nangamso Ngcwayi, Marco Boeri, Carol Mansfield, Linda-Gail Bekker and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 7 pooled it
1.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 7 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. The application of discrete choice experiments eliciting young peoples' preferences for healthcare: a systematic literature review.The European journal of health economics : HEPAC : health economics in prevention and care · 2023
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Assessing Non-Oral PrEP Alternatives Among Young Black Women in the Southern USA.Journal of racial and ethnic health disparities · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Alexandra M MinnisWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.ORCID 0000-0002-2943-2005
Millicent AtujunaThe Desmond Tutu HIV Centre, University of Cape Town, South Africa.ORCID 0000-0003-1287-2634
Erica N BrowneWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.ORCID 0000-0003-2069-6589
Sheily NdwayanaThe Desmond Tutu HIV Centre, University of Cape Town, South Africa.
Miriam HartmannWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.
Siyaxolisa SindeloThe Desmond Tutu HIV Centre, University of Cape Town, South Africa.
Nangamso NgcwayiThe Desmond Tutu HIV Centre, University of Cape Town, South Africa.
Marco BoeriHealth Preference Assessment, RTI Health Solutions, Belfast, Ireland.
Carol MansfieldHealth Solutions, RTI International, Research Triangle Park, NC, USA.
Linda-Gail BekkerThe Desmond Tutu HIV Centre, University of Cape Town, South Africa.ORCID 0000-0002-0755-4386
Elizabeth T MontgomeryWomen's Global Health Imperative, RTI International, San Francisco, CA, USA.ORCID 0000-0002-5477-4445
Desmond Tutu HIV Foundation · ZARTI International · USRTI Health Solutions · US

Funding

End-user research to optimize adherence to injectable HIV prevention approachesR01MH105262 · NIMH · RESEARCH TRIANGLE INSTITUTE · PI MONTGOMERY, ELIZABETH TRASK · 2015 to 2017
$1.8M
NIMH NIH HHS R01 MH105262NIMH NIH HHS R01MH105262
6 · The paper itself

Abstract

introductionExisting biomedical HIV prevention options, though highly effective, present substantial adherence challenges. End-user input on early-stage design of new HIV prevention approaches is critical to yielding products that achieve high uptake and adherence. The iPrevent Study examined youths' preferences for key attributes of long-acting Pre-Exposure Prophylaxis (PrEP), with a focus on characteristics pertinent to product delivery alongside key modifiable product attributes.

methodsA discrete choice experiment was conducted with female and male youth aged 18 to 24 in two high-density communities in Cape Town, South Africa during the period July 2017 to January 2019. Sexually active, PrEP-naïve youth were recruited using population-based sampling; targeted sampling was used to enrol men who have sex with men (MSM). In a series of nine questions, participants were asked to choose between two hypothetical products composed of five attributes (form, dosing frequency, access, pain, insertion site). We used a random-parameters logit model to estimate preference weights and trade-offs among product alternatives. We examined differences across three subgroups: females, men who have sex with only women (MSW) and MSM.

resultsA total of 807 participants (401 female) were enrolled with a median age of 21 years. Males included 190 MSM. Most youth had tested for HIV (95%) and reported being HIV-negative (91%). Across all groups, duration of effectiveness was the most important attribute, with strong preference for less frequent dosing. Injections were favoured over implants, though these preferences were strongest for females and MSM. Females preferred a product offered at a health clinic and disliked pharmacy access; all groups preferred the arm as the insertion site. Youth were willing to trade their preferred product form for longer duration.

conclusionsYouth indicated strong preferences for longer duration products. Each attribute nonetheless influenced preferences, offering insight into trade-offs that inform long-acting PrEP development.

Indexed as

Pre-Exposure ProphylaxisAdolescentAnti-HIV AgentsChoice BehaviorFemaleHIV InfectionsHomosexuality, MaleHumansMalePatient PreferenceSexual and Gender MinoritiesSouth AfricaYoung AdultAnti-HIV Agentsacceptabilityadolescent girls and young womendiscrete choice experimentHIV preventionlong-acting pre-exposure prophylaxismen who have sex with men

Identifiers

PMID32544303
PMCPMC7297460
OpenAlexW3034677347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.